News Medical on MSN5d
Multi-omic profiling sheds light on chemo-immunotherapy resistance in lung cancer
The study characterizes the lung cancer tumor microenvironment, linking cellular compositions to immunotherapy resistance and ...
Pharmaceutical Technology2d
Risk adjusted net present value: What is the current valuation of AstraZeneca’s Rilvegostomig?
Rilvegostomig is a monoclonal antibody commercialized by AstraZeneca, with a leading Phase III program in Non-Small Cell Lung Cancer.
Pharmaceutical Technology5d
Risk adjusted net present value: What is the current valuation of Immatics’s IMA-203?
IMA-203 is a gene-modified cell therapy commercialized by Immatics, with a leading Phase II program in Ovarian Cancer;Endometrial Cancer.
pharmaphorum23h
End of the line for MSD's TIGIT, LAG-3 cancer drugs
One LAG-3 drug has reached the market, namely Bristol-Myers Squibb's Opdualag, which combines its PD-1 inhibitor Opdivo ...
CTLA-4 Inhibitors Market to Advance at Moderate CAGR During the Study Period (2020-2034) | DelveInsight
CTLA-4 inhibitors are a well-established market in cancer care, and they are expected to grow significantly in the coming ...
Managed Healthcare Executive5d
ICER Identifies 5 Drugs with Unsupported Price Increases
The Institute for Clinical and Economic Review has identified five drugs — Biktarvy, Darzalex, Entresto, Cabometyx, and ...
Finanznachrichten1d
DelveInsight Business Research, LLP: CTLA-4 Inhibitors Market to Advance at Moderate CAGR During the Study Period (2020-2034) | DelveInsight
It is in late-stage clinical trials, either as a monotherapy or in combination with other treatments, targeting various cancers including non-small cell lung cancer, ovarian cancer, high-grade serous ...
Checkpoint Therapeutics Announces FDA Approval of UNLOXCYT™ (cosibelimab-ipdl)
UNLOXCYT (cosibelimab-ipdl) is indicated for the treatment of adults with metastatic cutaneous squamous cell carcinoma (“cSCC”) or locally advanced cSCC who are not candidates for curative surgery or ...
Checkpoint Therapeutics Announces FDA Approval of UNLOXCYT(TM) (cosibelimab-ipdl)
UNLOXCYT (cosibelimab-ipdl) is indicated for the treatment of adults with metastatic cutaneous squamous cell carcinoma (“cSCC”) or locally advanced cSCC who are not candidates for curative surgery or ...
Finanznachrichten4d
Checkpoint Therapeutics, Inc: Checkpoint Therapeutics Announces FDA Approval of UNLOXCYT (cosibelimab-ipdl)
About Cutaneous Squamous Cell Carcinoma Cutaneous squamous cell carcinoma ... as a potential new treatment for patients with EGFR mutation-positive non-small cell lung cancer. Checkpoint is ...